louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02137616: Antipsychotic to Treat Psychosis Syndrome
Official title: Effectiveness of Antipsychotic Drugs to Treat Psychosis Syndrome: an Open Label, Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Psychotic Disorders
Keywords: psychosis
syndrome
risk
antipsychotic
Lead sponsor: Central South University
Sponsor class: OTHER
First posted: 2014-05-14
Enrollment: 300
Sex: ALL
Minimum age (years): 16
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study assess the safety and effects of atypical antipsychotics in subjects with psychosis syndrome and psychosis risk syndrome.

Detailed description: The investigators investigated whether administration of atypical antipsychotics could alleviate prodromal symptoms and be well tolerated by subjects with psychosis syndrome and psychosis risk syndrome.

Eligibility criteria: Inclusion Criteria:

* were help-seeking young individuals in outpatients service
* aged 16-30 years
* fitted one of the following Criteria: Psychosis-risk Syndromes (COPS-SIPS) or Psychotic Syndrome (POPS-SIPS) or DSM-IV diagnosis of schizophreniform disorder

Exclusion Criteria:

* a previous diagnosis of any psychotic disorder or bipolar disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition;
* symptoms fully accounted for by an Axis 1 disorder or sequelae of drug/alcohol use;
* neurological disorders or organic disorders affecting the central nervous system, substance-related disorders or mental retardation as defined by the DSM-IV criteria;
* history treatment of antipsychotic or antidepression, mood stabilizers or electroconvulsive therapy;
* diagnosed as having a serious and unstable medical condition.

Primary outcomes:
measure: Changes of PANSS total scores from baseline to 18 months
timeFrame: 18 months
Secondary outcomes:
measure: Social function
timeFrame: 18 months
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: 18 months
Other outcomes:
Locations:
city: Changsha
country: China
facility: the Second Xiangya Hospital
state: Hunan
Study officials:
affiliation: the second xiangya hospitcal
name: xiaofeng Guo, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03507816: A Multidrug-resistant (MDR) and Extensively Drug- Resistant (XDR) Tuberculosis Study in Alsace
Official title: Epidemiology and Treatment of Multidrug-resistant (MDR TB) and Extensively Drug- Resistant (XDR TB) Tuberculosis in Strasbourg, France; a 10 Years Retrospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tuberculosis
Keywords: Tuberculosis
Multi-drug Resistant Tuberculosis
Observational retrospective study
Clinical epidemiology
Treatment outcome
Migrant
Precarity
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2018-04-25
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with proven MDR or XDR tuberculosis

Brief summary: The purpose of this study is to examine the epidemiology of TB MR in Strasbourg and evaluate the second-line anti-tuberculosis treatments effectiveness, and the relevance and adequacy of the treatments with WHO recommendations. During years 2006-2016, all new cases of MDR TB or XDR TB diagnosed Strasbourg University Hospital will be included in the study (22 cases). Data were collected from the Center for Tuberculosis Control (CLAT) records, the patient's medical records.


Eligibility criteria: Inclusion Criteria:

* Major patient (≥18 years old)
* Patient hospitalized at Strasbourg University Hospital from 2006 to 2016, with proven MDR or XDR tuberculosis

Exclusion Criteria:

- Refusal of the patient to participate in the study

Primary outcomes:
measure: Study of clinical characteristics of patients hospitalized at Strasbourg University Hospital from 2006 to 2016, with proven MDR or XDR tuberculosis
timeFrame: The period from January 1st, 2006 to December 31st, 2016 will be examined
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Maladies Infectieuses et Tropicales
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Xavier ARGEMI, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06428916: Facilitated Tucking Position During Endotracheal Suctioning
Official title: The Effect of Facilitated Tucking Position During Endotracheal Suctioning on Physiological Measurement and Behavioral Responses of the Preterm Neonates
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Distress Syndrome
Keywords: Physiological measurement
Behavioral Responses of the Preterm Neonates
Facilitated Tucking Position
Endotracheal Suctioning
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2024-05-24
Enrollment: 40
Sex: ALL
Minimum age (years): 32
Maximum age (years): 36
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Aim of the present study The present study will aimed to determine the effect of facilitated tucking position during endotracheal suctioning on physiological criteria and behavioural responses of the preterm neonates.

Research Hypotheses

1. Preterm neonates who receive facilitated tucking position during endotracheal suctioning exhibit more stable physiological criteria than those who do not.
2. Preterm neonates who receive facilitated tucking position during endotracheal suctioning exhibit more stable behavioral responses than those who do not.


Eligibility criteria: Inclusion Criteria:

* Gestational age between 32 and 36 weeks, weight 1200 grams or greater.
* Postnatal age: two days after delivery to allow for resolution of analgesia or anesthesia received by their mothers during labor.
* Have endotracheal intubation.

Exclusion Criteria:

* Preterm neonates who have congenital anomalies or neurological malformations, intracranial hemorrhage, seizures.
* Preterm neonates who received sedatives within four hours before the intervention
* Preterm neonates who exposed to any uncomfortable procedure for at least 30 minutes prior to the intervention.

Primary outcomes:
measure: Change from baseline of heart rate of preterm neonates on Neonates' Physiological Assessment Tool during and immediately following the endotracheal suction procedure
timeFrame: during procedural and immediately after procedure
measure: Change from baseline of Respiratory Rate of preterm neonates on Neonates' Physiological Assessment Tool during and immediately following the endotracheal suction procedure
timeFrame: during procedural and immediately after procedure
measure: Change from baseline of oxygen saturation in blood of preterm neonates on Neonates' Physiological Assessment Tool during and immediately following the endotracheal suction procedure
timeFrame: during procedural and immediately after procedure
Secondary outcomes:
measure: change of baseline of Neonates' behavioral states on Anderson Behavioral State Scale during and immediately following the endotracheal suction procedure
timeFrame: during procedural and immediately after procedure
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Kafrelsheikh University
state: Kafr el-Sheikh
Study officials:
References:
Clinical trial NCT02177916: Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation
Official title: "A Comparison of 2 Different Methods of Patient Education to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lung Transplantation
Keywords: lung transplantation
Lead sponsor: Tampa General Hospital
Sponsor class: OTHER
First posted: 2014-06-30
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: The Lung Transplant Team at Tampa General Hospital has identified a need to improve both the quality and quantity of the education that is provided to patients listed for lung transplantation. We propose to change the method and timing of our transplant patient education. The objective of this prospective data collection will be to collect and analyze pre and post test scores of patients when patient education is provided via compact disc as compared to individualized teaching.


Eligibility criteria: Inclusion Criteria:

* Age- 18-75

Exclusion Criteria:

* None

Primary outcomes:
measure: Effectiveness of patient education when provided via compact disk as compared to individualized teaching as assessed by pre and post test scores.
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Tampa General Hospital
state: Florida
Study officials:
affiliation: Tampa General Hospital
name: Mark Rolfe, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02686216: Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )
Official title: Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer's Disease
Keywords: F-18 THK-5351 PET
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2016-02-19
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Biodistribution, pharmacokinetics, and safety of F-18 THK-5351 PET in Alzheimer's disease patients and healthy subjects.

Detailed description: Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably Alzheimer's dementia patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.

Eligibility criteria: Healthy Inclusion Criteria:

* Neurologic testing. (MMSE 24-30, Wechsler Logical Memory score \>5).
* Subjects must provide written inform consent.

Patients with AD Inclusion Criteria:

* Diagnosis of AD according to the clinical diagnostic criteria of "possible AD" with NINCDS-ADRDA criteria
* MMSE 20-26, Clinical dementia rating 0.5 or 1, Wechsler Logical Memory score\<=4
* Patient who provide a written informed consent prior to study entry. (If the patient is incapable informed consent, the caregiver may consent on behalf of the patient. The caregiver should be able to report activities of daily living and their mental status.)

Exclusion Criteria:

* Pregnant or become pregnant
* Current breast feeding
* Clinically significant abnormal laboratory values
* Unstable medical or psychiatric illness.
* Cardiovascular disease (cardiac surgery or myocardial infarction within the last 6 months; unstable angina; decompensated congestive heart failure; significant cardiac arrhythmia; congenital heart disease).
* History of drug or alcohol abuse within the last year, or prior prolonged history of abuse. --History of severe allergic or anaphylactic reactions particularly to the tested drugs .
* PI assessment with high risk.

Primary outcomes:
measure: The primary outcome measures are to evaluate the dosimetry of novel radiotracer F-18 THK-5351 in human.
timeFrame: One year
Secondary outcomes:
measure: Optimal scanning time for brain imaging using F-18 THK-5351.
timeFrame: One year
Other outcomes:
Locations:
Study officials:
References:
citation: Hsiao IT, Lin KJ, Huang KL, Huang CC, Chen HS, Wey SP, Yen TC, Okamura N, Hsu JL. Biodistribution and Radiation Dosimetry for the Tau Tracer 18F-THK-5351 in Healthy Human Subjects. J Nucl Med. 2017 Sep;58(9):1498-1503. doi: 10.2967/jnumed.116.189126. Epub 2017 Mar 23.
Clinical trial NCT04971616: Risk Screening and Assessment of Shoulder, Neck and Lower Back Discomfort.
Official title: Risk Screening and Assessment of Shoulder, Neck and Lower Back Discomfort.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Low Back Pain
Neck Pain
Shoulder Pain
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-21
Enrollment: 300
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 20-40 year of age with shoulder, neck and lower back discomfort

Brief summary: Identifying high-risk factors that may lead to shoulder, neck and lower back discomfort and contributing to the primary prevention of disease progression.

Detailed description: The purpose of this study is to design a self-assessment scheme for clinical assessment of shoulder, neck and lower back function and compare the consistency between clinical assessment and self-assessment. The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices, evaluating the risk factors of shoulder, neck and lower back discomfort.

Eligibility criteria: Inclusion Criteria

* 20-40 year of age with symptoms of shoulder
* Neck and lower back discomfort

Exclusion Criteria

* Red flag sign of the neck

Primary outcomes:
measure: Range of motion (ROM) of the neck
timeFrame: at least 2-week monitoring by wearable devices
measure: Oswestry Disability Index (ODI)
timeFrame: at least 2-week monitoring by wearable devices
measure: Visual Analogue Scale (VAS)
timeFrame: at least 2-week monitoring by wearable devices
measure: Roland-Morris Disability Questionnaire (RDQ)
timeFrame: at least 2-week monitoring by wearable devices
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
Study officials:
affiliation: Peking University Third Hospital
name: Jian-quan Wang, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT05109416: Glossopharyngeal Nerve Block on Post Tonsillectomy Pain Among Egyptian Children
Official title: Glossopharyngeal Nerve Block on Post Tonsillectomy Pain Among Egyptian Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Post Tonsillectomy Pain
Keywords: Glossopharyngeal nerve block
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2021-11-05
Enrollment: 210
Sex: ALL
Minimum age (years): 7
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Tonsillectomy is one of most common performed surgical procedure in children . tonsillectomy or adenotonsillectomy have high incidence of Post operative pain , it is very important and significant problem because it can lead to decrease oral intake and dehydration

Detailed description: Tonsillectomy is one of the most common performed surgical procedure in children. Tonsillectomy or adenotonsillectomy have high incidence of Post operative pain incidence . There is still debate about the optimal analgesia for this common procedure , different methods have been described including intraoperative anesthetic pain regimens , adjustment of surgical technique , intraoperative local anesthetic injection and use of pharmacotherapy post operative .

The main goal of the preventive analgesia is the pain releif with minimum side effect . The objective of this study is to investigate and compare the effect of Glossopharyngeal nerve block for relief of pain on children following adenotonsillectomy .

This is prospective , double blinded , randomized study

Eligibility criteria: Inclusion Criteria:

* average weight is 10_50 kg
* patient is generally stable
* indication of tonsillectomy is recurrent tonsillitis
* Ability to self report pain

Exclusion Criteria:

* Hypersensitivity to bupivacaine
* Obstructive sleep apnea syndrome
* Pulmonary or cardic diseases

Primary outcomes:
measure: The first call for analgesia
timeFrame: In 24 hours
Secondary outcomes:
measure: The analgesic consumption
timeFrame: In 24 hours
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Faculty of Medcine
Study officials:
References:
Clinical trial NCT06142916: The Effect of Virtual Reality Training on Mental Health Literacy and Stigma
Official title: THE EFFECT OF TRAINING PROVIDED WITH VIRTUAL REALITY ON NURSES' MENTAL HEALTH LITERACY AND STIGMA LEVEL TOWARDS MENTAL DISEASES
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Mental Health Disorder
Literacy
Stigma, Social
Keywords: Mental Health Disorder
Mental Health Literacy
Stigma
Virtual Reality
Lead sponsor: Uskudar University
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Purpose: This study will be conducted to examine the effect of virtual reality training on nurses' mental health literacy and stigma level towards mental illnesses.

Design: The study is a randomized controlled experimental research. Method: The population of the research consists of 110 nurses working in a public hospital. Power analysis was performed with G\* Power software to determine the number of nurses constituting the research sample. The sample size was determined as 25 people in each group. Considering that there may be data loss in the study, it is planned to include 30 people in the intervention group and 30 people in the control group. Nurses who volunteer to participate in the study and fill out the pre-test will be randomly assigned to the groups using the Statistical Analysis Software program to ensure random distribution to the intervention and control groups. Personal Information Form, Mental Health Literacy Scale (MHLS) and Opening Minds Stigma Scale for Healthcare Providers (OMS-HC) will be used in study data collection.

Hypotheses:

H1: The mental health literacy level of nurses who receive training with virtual reality is higher than nurses who receive classical training.

H2: The level of stigmatization towards mental illnesses of nurses trained with virtual reality is lower than nurses who received classical training.


Eligibility criteria: Inclusion Criteria:

* Being 18 years or older
* Becoming a nurse
* Being actively working in a public hospital in Istanbul
* Volunteering to participate in the study
* Not having worked in a psychiatric ward before

Exclusion Criteria:

Being under 18 years of age

* Not being a nurse
* Not actively working in the hospital where the study will be conducted
* Not volunteering to participate in the study
* Having worked in a psychiatric ward before

Primary outcomes:
measure: Personal Information Form
timeFrame: For 2 weeks
measure: Mental Health Literacy Scale
timeFrame: For 2 weeks
measure: Stigma Scale for Mental Illnesses for Health Care Workers
timeFrame: For 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05359016: Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
Official title: Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cervical Cancer
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Population Services International
name: Eduardo Mondlane University
name: William Marsh Rice University
First posted: 2022-05-03
Enrollment: 14600
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The goal of this operational research study is to develop, implement and test integrated CCS\&PT and voluntary FP service delivery models to evaluate whether integrated service delivery can optimize uptake and health impact of both services. The study objectives and learning questions are listed below, along with key outcomes that will be measured.

Detailed description: Objectives:

The study objectives are outlined below:

1. To quantify the health impact of CCS\&PT on the uptake of voluntary FP services.
2. To quantify the health impact of voluntary FP on the uptake of CCS\&PT services.
3. To determine which promotional strategies are most effective to increase uptake of CCS\&PT services.
4. To identify cost to deliver high quality CCS\&PT services integrated into existing voluntary FP programs.
5. To determine client and provider acceptability of integrated CCS\&PT and voluntary FP services using new screen and treat technologies.

Eligibility criteria: Inclusion Criteria:

* Women 30 - 49 years or all women living with HIV
* Not currently pregnant
* Patients with a cervix (women who have undergone a total hysterectomy with removal of the cervix are not eligible)
* Living in Maputo or Gaza
* Willing and able to provide informed consent for services.

Exclusion Criteria:

* Not meeting the inclusion criteria
* Physical or mental impairment that inhibits participation in the study
* Pregnant women

Primary outcomes:
measure: Number of women who will undergo Cervical Cancer Screening by HPV testing
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Kathleen Schmeler, MD
role: PRINCIPAL_INVESTIGATOR
References: